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Retinoid-Induced Epidermal Hyperplasia Is Mediated
by Epidermal Growth Factor Receptor Activation Via
Specific Induction of its Ligands Heparin-Binding EGF
and Amphiregulin in Human Skin In Vivo
Laure Rittie´1, James Varani2, Sewon Kang1, John J. Voorhees1 and Gary J. Fisher1
Retinoids are widely used in the treatment of photoaging to stimulate dermal repair. However, retinoids also
induce epidermal hyperplasia, which can lead to excessive scaling. Scaling is the major deterrent to topical
retinoid therapy. Keratinocyte growth is strongly stimulated via ligand activation of EGFR. We examined
regulation of EGFR ligands by retinoids and the role of EGFR in retinoid-induced hyperplasia in human skin in
vivo. Topical treatment of human skin with all-trans retinoic acid (tRA) induces EGFR ligands heparin-binding
(HB)-EGF and amphiregulin (AR), and reduces betacellulin mRNA levels. Laser capture microdissection-coupled
real-time reverse transcription-PCR reveals that tRA increases HB-EGF mRNA throughout the epidermis,
whereas AR induction is limited to basal keratinocytes. Topical tRA activates extracellular signal-regulated kinase
1/2 (Erk1/2) downstream EGFR effectors in human skin in vivo. tRA increases the soluble forms of AR and HB-EGF
proteins, and induces epidermal hyplasia, in human skin organ culture. Neutralization of HB-EGF or AR with
specific antibodies strongly reduces tRA-induced epidermal hyperplasia. Finally, inhibition of EGFR activation by
genistein reduces epidermal hyperplasia caused by topical retinoid treatment. These data demonstrate the
central role of EGFR activation in retinoid-induced epidermal hyperplasia, and suggest that EGFR inhibitors can
mitigate retinoid-induced scaling.
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INTRODUCTION
Retinoids have been widely used for the treatment of
numerous dermatological disorders, including psoriasis,
acne, skin cancer, and skin aging (Futoryan and Gilchrest,
1994; Zouboulis, 2001). In the treatment of aging, retinoids
improve dermal functions, that is, increase fibroblast pro-
liferation (Varani et al., 2000) and collagen production
(Griffiths et al., 1993), and decrease matrix metalloproteinase-
mediated extracellular matrix degradation (Fisher et al.,
1996). However, retinoid-induced improvement of dermis
is accompanied by epidermal hyperplasia, which can lead to
excessive scaling (Kang et al., 1995). Scaling is the major
deterrent to topical retinoid use. The mechanism(s) by which
retinoids increase epidermal proliferation in human skin in
vivo is largely unknown.
All-trans retinoic acid (tRA) increases proliferation of basal
keratinocytes, inducing accelerated turnover of epidermal
cells and thickening of epidermis (Fisher and Voorhees, 1998;
Weiss et al., 1988; Varani et al., 2001). The EGFR pathway is
the major mitogenic pathway for human keratinocytes (Stoll
et al., 2001). The EGFR (ErbB) family contains four members:
EGFR (ErbB1), ErbB2, ErbB3, and ErbB4. EGFR, ErbB2, and
ErbB3 are expressed in normal human epidermis (Hudson
and McCawley, 1998; Stoll et al., 2001). Ligand activation of
EGFR directly stimulates keratinocyte proliferation (Hudson
and McCawley, 1998), whereas ErbB2 has no known ligand,
and ligand activation of ErbB3 is not mitogenic for human
keratinocytes (Stoll et al., 2001). EGFR ligands include EGF,
amphiregulin (AR), betacellulin (BTC), epiregulin (EPI),
heparin-binding EGF-like growth factor (HB-EGF), and
transforming growth factor-a (TGF-a) (Marmor et al., 2004).
AR and TGF-a have been shown to directly stimulate
keratinocyte growth (Coffey et al., 1987).
Ligand activation of EGFR induces receptor homo- or
heterodimerization (primarily with ErbB2), which increases
EGFR tyrosine phosphorylation. Phosphotyrosine residues
on the C-terminus of the receptor act as docking sites
for assembly of signaling complexes that mediate cellular
responses.
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It was previously shown, in a transgenic mouse model,
that tRA induces HB-EGF in suprabasal keratinocytes
(Xiao et al., 1999). Induction of HB-EGF mRNA has also
been reported following tRA treatment of cultured human
keratinocytes and human skin (Stoll and Elder, 1998), human
skin organ cultures (Varani et al., 2001), and in vitro
reconstructed skin (Bernard et al., 2002). The use of HB-
EGF-specific antibodies or EGFR tyrosine kinase inhibitor
reduced tRA-induced epidermal hyperplasia in skin organ
culture (Varani et al., 2001).
The aim of this study was to investigate the role of EGFR
and its ligands in retinoid-induced epidermal hyperplasia in
human skin in vivo. Our data support the concept that tRA-
induced keratinocyte proliferation is mediated by the
activation of EGFR pathway by increased levels of AR and
HB-EGF in human skin in vivo.
RESULTS
Quantitative gene expression of EGFR ligands in normal human
skin in vivo
To study EGFR signaling pathway in human epidermis, we
assessed gene expression levels of EGFR ligands, AR, BTC,
EGF, EPI, HB-EGF, and TGF-a. We quantified relative mRNA
levels for each ligand using real-time reverse transcription
(RT)-PCR, in skin samples from eight healthy individuals.
TGF-a mRNA was the most highly expressed (Figure 1). AR,
BTC, EPI, and HB-EGF were expressed at similar levels,
approximately five times lower than TGF-a. EGF mRNA
levels were 350 times lower than those of TGF-a (Figure 1).
Retinoids enhance AR and HB-EGF mRNA levels in human skin
in vivo
We next treated human skin topically with vehicle, tRA, or
all-trans retinal (tROL), and determined EGFR ligand mRNA
levels. As shown in Figure 2a, 0.1% tRA treatment induced a
substantial increase in AR and HB-EGF mRNA. Maximal
induction (8.8-fold) of AR mRNA was detected 16 hours after
tRA application. Maximal induction (10.6-fold) of HB-EGF
mRNA occurred 24 hours after tRA application. AR and HB-
EGF mRNA levels remained elevated for at least 4 days of
treatment. tRA modestly and transiently increased EPI mRNA
levels, which were increased 2.7-fold compared to vehicle-
treated skin, 24 hours after initiation of treatment (Figure 2a).
EPI mRNA levels were back to control levels 48 hours after
tRA application.
tRA induced a marked reduction of BTC mRNA, which
was decreased 80% compared to control, 24 hours after tRA
application. This inhibition was maintained for at least 4 days
of treatment (Figure 2b). No alteration of TGF-a or EGF
mRNA levels was detected during the course of tRA treatment
of human skin in vivo (Figure 2b).
The pattern of EGFR ligand mRNA induction after topical
tROL (0.4%) treatment was very similar to that observed with
tRA treatment. This observation is consistent with the fact that
tROL needs to be converted into tRA in order to exert its
activity (Kurlandsky et al., 1994). tROL induced AR and
HB-EGF mRNA levels 5.2- and 5.9-fold, respectively,
24 hours after initiation of treatment (Figure 3a). After 4 days
of treatment, AR and HB-EGF mRNA levels remained 5.3-
and 8.1-fold higher than controls, respectively. tROL did not
alter EPI (Figure 3a), EGF, or TGF-a (Figure 3b) mRNA
expression. tROL reduced BTC mRNA synthesis by 80%
relative to vehicle-treated skin (Figure 3b). This decrease was
maintained for at least 4 days of treatment.
tRA enhances AR and HB-EGF mRNA synthesis in basal and
suprabasal keratinocytes in human skin in vivo
Using laser capture microdissection, we determined AR,
HB-EGF, and BTC mRNA levels in basal and suprabasal
keratinocytes in normal human skin. The origin of the cells
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Figure 1. EGFR ligands are expressed in normal human skin in vivo. Total
RNA was isolated from whole punch biopsies and analyzed by real-time
RT-PCR for AR, BTC, EGF, EPI, HB-EGF, and TGF-a mRNA expression in
normal human skin, as described in Materials and Methods. Data are
mean7SEM from eight subjects.
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Figure 2. Topical tRA induces AR, HB-EGF, and EPI, decreases BTC, and
does not alter EGF and TGF-a in normal human skin in vivo. Adult volunteers
were treated with vehicle or 0.1% tRA under occlusion as described in
Materials and Methods. Biopsies were taken 8, 16, 24, 48, 72, and 96 hours
after the beginning of the treatment, and mRNA expression for (a) AR, HB-
EGF, EPI and (b) BTC, EGF, and TGF-a was analyzed by real-time RT-PCR.
Data are fold changes in mRNA levels in tRA versus vehicle-treated site.
Values represent mean7SEM from eight subjects. *Po0.05 vs vehicle.
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was confirmed by analysis of keratin 5 (basal keratinocytes)
and keratin 10 (suprabasal keratinocytes) expression, which is
not altered by topical retinoid treatment in human skin in
vivo (Fisher and Voorhees, 1996). For each sample, keratin 5
mRNA was at least five-fold more abundant in basal relative
to suprabasal samples, and keratin 10 mRNA was at least five
times higher in suprabasal vs basal samples (data not shown).
Dermal cells, isolated as control, contained no detectable
keratin 5 or 10 mRNA (data not shown).
Analysis of vehicle-treated skin revealed that AR, BTC, and
HB-EGF mRNA were predominantly expressed in suprabasal
compared to basal keratinocytes (Figure 4a). AR mRNA was
detected both in basal and suprabasal cells, with 8.6-fold
higher levels in suprabasal vs basal keratinocytes. HB-EGF
mRNA was near the limit of detection in basal cells (nine-fold
lower than in suprabasal cells) and BTC mRNA was not
detected in basal keratinocytes.
Twenty-four hours after topical tRA application, AR was
induced primarily in the basal layer, whereas HB-EGF was
induced in both basal and suprabasal layers (Figure 4b). BTC
mRNA could not be reliably measured in either basal or
suprabasal layers following tRA treatment (data not shown).
tRA increases AR protein levels in human skin in vivo
We next treated human skin topically with vehicle or tRA for
24 hours and prepared epidermal extracts to measure AR and
HB-EGF protein by ELISA. AR protein was increased by 3.3-
fold after tRA treatment (14.40710.80 pg/mg total protein in
vehicle site vs 47.46715.94 pg/mg total protein in tRA site,
n¼3, Po0.05). We were unable to reliability extract and
measure HB-EGF protein levels in these samples.
tRA increases the processed forms of AR and HB-EGF proteins
in human skin organ cultures
To further investigate tRA regulation of AR and HB-EGF
protein expression, we used human skin organ cultures, in
which tRA also induces epidermal hyperplasia (Varani et al.,
2001). Fresh biopsies were cultured for 3 days with or
without 3 mM tRA. At the end of the incubation period,
conditioned supernatants were harvested and concentrations
of AR and HB-EGF were measured by ELISA. As shown in
Figure 5a and b, tRA treatment increased the soluble,
secreted AR and HB-EGF proteins by 3.5- and 2.5 fold,
respectively.
tRA activates Erk1/2 in human skin in vivo
A single 6-mm punch biopsy does not provide sufficient
material to detect EGFR phosphorylation by Western blot
(Fisher et al., 1998). Therefore, we used extracellular signal-
regulated kinase (Erk) phosphorylation as a surrogate for
EGFR activation. Ligand activation of EGFR results in
increased EGFR tyrosine phosphorylation and activation of
downstream effectors such as Erk1/2 (Marmor et al., 2004).
Healthy volunteers were treated in buttock skin with vehicle
or tRA for 32 hours. Punch biopsies were obtained, and total
and phospho-Erk were determined by Western blot. As
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Figure 3. Topical tROL induces AR, and HB-EGF, decreases BTC, and does
not alter EGF, EPI, and TGF-a in normal human skin in vivo. Adult volunteers
were treated with vehicle or 0.4% tROL under occlusion as described in
Materials and Methods. Biopsies were taken 24, 48, 72, and 96 hours after the
beginning of the treatment, and mRNA expression for (a) AR, HB-EGF, EPI and
(b) BTC, EGF, and TGF-a was analyzed by real-time RT-PCR. Data are fold
changes in mRNA levels in tROL versus vehicle-treated site. Values represent
mean7SEM from seven subjects. *Po0.05 vs vehicle.
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Figure 4. Subepidermal localization of AR, HB-EGF, and BTC mRNA in
normal human skin in vivo before and after tRA treatment. Adult volunteers
were treated for 24 hours with vehicle or 0.1% tRA. Basal and suprabasal
keratinocytes were isolated by laser capture microdissection, and RNA from
captured cells analyzed by real-time RT-PCR for AR, HB-EGF, and BTC.
(a) mRNA sublocalization in vehicle-treated skin. (b) Fold change in AR and
HB-EGF mRNA levels in tRA- (white bars) versus vehicle-treated skin (black
bars). Data are means7SEM from four subjects. *Po0.05 vs (a) basal
keratinocytes and (b) vehicle.
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shown in Figure 6, 32-hour treatment with tRA induced a 2.5-
fold increase in Erk1/2 phosphorylation compared to vehicle.
tRA-induced epidermal hyperplasia is blocked by AR and
HB-EGF neutralizing antibodies in human skin organ culture
To determine whether AR or HB-EGF were directly involved
in tRA-induced epidermal hyperplasia, human skin organ
cultures were treated with tRA in the presence of control or
neutralizing antibody. tRA induced a marked increase in
epidermal thickness (Figure 7). Although control IgGs did not
alter tRA-induced epidermal hyperplasia, treatment with
either anti-HB-EGF or anti-AR resulted in a marked decrease
of RA-induced epidermal hyperplasia, by 51 and 81%,
respectively (Figure 7).
Topical genistein inhibits tRA-induced keratinocyte growth,
without affecting AR and HB-EGF gene expression levels, in
human skin in vivo
To further examine the role of EGFR pathway in tRA-induced
keratinocyte hyperproliferation in human skin in vivo, we
utilized the EGFR tyrosine kinase inhibitor genistein, an
isoflavone found in soybean (Akiyama et al., 1987; Kang
et al., 2003). Subjects were treated topically with vehicle,
tROL, or tRA, with or without genistein for 3 days. Figure 8
shows the relative changes in the number of Ki-67-positive
cells for each condition. As described previously (Varani
et al., 2001), tROL and tRA increased the number of Ki-67-
positive cells. Topical treatment of human skin with 1%
genistein reduced tROL- and tRA-induced keratinocyte
proliferation by approximately 70 and 60%, respectively
(Figure 8). Genistein treatment did not alter tROL- and
tRA-mediated increase of AR and HB-EGF mRNA levels (data
not shown).
DISCUSSION
Taken together, recent studies conducted in cell culture,
organ culture, and in animal models support the concept that
retinoid-induced keratinocyte proliferation is mediated by
EGFR activation through induction of its ligand HB-EGF (Stoll
and Elder, 1998; Xiao et al., 1999; Varani et al., 2001). We
have extended these observations to human epidermis in
vivo. Our results indicate that, in contrast to what is observed
in mouse skin, tRA-mediated modulation of EGFR ligands is
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Figure 5. tRA induces AR and HB-EGF proteins in human skin organ culture
in vitro. Full-thickness punch biopsies were cultured with or without 3 mM
tRA for 3 days. At the end of the incubation period, supernatants were
harvested and assayed for (a) AR and (b) HB-EGF proteins by ELISA. Data are
mean7SEM from four experiments. *Po0.05 vs control.
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Figure 6. tRA enhances Erk1/2 phosphorylation in human skin in vivo. Adult
volunteers were treated with vehicle or 0.1% tRA under occlusion for
32 hours. Epidermal lysates were prepared and analyzed for phospho-
and total Erk1/2 by Western blot. Band intensities were quantified by
PhosphorImager. Data are mean7SEM from four experiments. Inset shows
a representative Western blot. *Po0.05 vs vehicle.
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Figure 7. Retinoid-induced epidermal hyperplasia is blocked by AR and
HB-EGF neutralizing antibodies. Full-thickness punch biopsies were cultured
with or without 3 mM tRA, supplemented with blocking antibodies to HB-EGF,
AR, or control IgGs. At the end of the incubation period, epidermal thickness
was measured after hematoxylin and eosin staining. Data are mean7SEM
from nine experiments. *Po0.05 vs control; #Po0.05 vs tRA.
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Figure 8. Topical genistein inhibits tRA-induced epidermal hyperprolifera-
tion in human skin in vivo. Adult volunteers were treated for 3 days with
vehicle, 0.4% tROL, or 0.1% tRA with or without 1% genistein. Biopsies were
taken at the end of the treatment period and keratinocyte growth was
determined as Ki-67-positive cells. Data are mean7SEM from five subjects.
*Po0.05 vs vehicle; #Po0.05 vs retinoid alone.
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not limited to HB-EGF. In human skin in vivo, retinoids
induce AR and HB-EGF and reduce BTC mRNA steady-state
levels, without affecting basal levels of EPI, TGF-a, or EGF.
We find that EGFR activation plays a central role in retinoid-
induced epidermal cell growth in human skin in vivo.
Blocking EGFR tyrosine kinase activity by genistein reduces
retinoid-induced epidermal cell growth in human skin in
vivo.
We noted several differences in the tRA regulation of
EGFR ligands between human and mouse epidermis. First,
HB-EGF mRNA induction reaches a maximal levelB6 hours
after tRA application in mouse skin (Xiao et al., 1999),
whereas induction is maximal 24 hours after initiation of
treatment in human skin (Figure 2a). This difference in
kinetics likely reflects that the stratum corneum, which
provides a barrier for penetration of tRA into the living
layers of skin, is approximately twice as thick in human
skin compared to mouse skin (B17 vs B9 mm) (Marks,
2004). Another striking difference between mouse and
human skin is that tRA induces AR in human, but not
in mouse skin (Xiao et al., 1999). Interestingly, AR is
increased after tRA treatment in human skin organ culture
(Figure 5a), but not in reconstructed skin in vitro (Bernard
et al., 2002). In mouse skin, AR mRNA is detectable by
Northern blot, but is unchanged after topical tRA treat-
ment (Xiao et al., 1999). AR mRNA levels are inducible in
mouse skin in response to other conditions that disrupt the
skin permeability barrier, for example, by solvents or tape
stripping (Liou et al., 1997).
The mechanism by which retinoids induce EGFR ligand
synthesis remains unclear. Retinoids exert their biological
effects through binding to nuclear RA receptors (RARs), and
retinoid X receptors (RXR), which belong to the superfamily
of nuclear hormone receptors. Among the different isoforms,
adult human skin expresses predominantly RAR-g and RXR-a
(Elder et al., 1991; Fisher et al., 1994). Upon binding to their
ligand, retinoid receptors heterodimerize and act as trans-
cription factors, which bind to specific regions of promoter
sequences called RA response elements. Transgenic mouse
studies revealed that targeted overexpression of dominant-
negative RXR-a (Feng et al., 1997), or RAR-g (Xiao et al.,
1999), or targeted disruption of RXR-a and RAR-g (Chapellier
et al., 2002) in suprabasal keratinocytes, prevents topically
applied tRA from stimulating proliferation of epidermal
keratinocytes. Taken together, these studies indicate that
suprabasal expression of functional RAR/RXR is required for
tRA-mediated epidermal hyperplasia and HB-EGF induction,
at least in mice. However, examination of the published
sequences of HB-EGF (Fen et al., 1993) and AR (Plowman
et al., 1990) does not reveal any putative RA response
elements. Although the existence of yet unidentified RA
response elements upstream or downstream of the previously
reported promoter regions is difficult to rule out, a direct
modulation of HB-EGF or AR promoters seems unlikely.
Alternatively, RAR/RXR may regulate other transcription
factor(s) that would directly regulate AR and HB-EGF gene
expression. The identity of such transcription factor(s)
remains to be determined.
Interestingly, tRA downregulates BTC in human skin.
BTC is also reduced in psoriasis lesions, characterized by
hyperproliferative epidermis (Piepkorn et al., 2003). The
membrane-bound precursor of BTC contains an RGD
sequence, which binds extracellular matrix protein receptors
(integrins), in its extracellular domain. It has been suggested
that BTC acts as a membrane-anchored integrin ligand,
mediating cell–cell interactions (Dunbar and Goddard, 2000).
In this case, downregulation of BTC would decrease cell–cell
cohesion, which conceivably could promote cell prolifera-
tion and/or migration. Further experiments are required to test
this possibility.
Topical tRA treatment induced a marked increase in AR
protein levels in whole epidermal extracts. However, we
were unable to reproducibly quantify HB-EGF protein
because their levels were very low, approximately 10-fold
lower than AR, despite a similar mRNA copy number in
human skin. Whether this difference reflects a lower
extraction yield and/or a shorter half-life of the protein is
unknown. However, it is interesting to note that, in human
keratinocytes in culture, activation of EGFR pathway shortens
the half-life of HB-EGF transcripts and stabilizes AR mRNA
(Stoll and Elder, 1999). Further experiments would be needed
to determine whether the two transcripts are similarly
regulated in human epidermis in vivo.
Using human skin organ cultures, we consistently
measured increased levels of both AR and HB-EGF proteins
after tRA treatment. Our results demonstrate that (i) tRA
increases AR and HB-EGF protein levels, and (ii) the two
growth factors are processed and released in their soluble
forms after retinoid treatment.
Our data demonstrate that AR, BTC, and HB-EGF mRNA
are expressed primarily in the suprabasal cells of normal
epidermis. Predominantly suprabasal expression of AR was
previously demonstrated by in situ hybridization in human
skin (Schelfhout et al., 2002). tRA treatment induces HB-EGF
in both basal and suprabasal layers, whereas AR induction is
more limited to basal keratinocytes. These findings reveal that
these two growth factors are regulated differently in a manner
that is dependent on the stage of keratinocyte maturation.
The mechanisms involved in this maturation-dependent
regulation remain to be elucidated.
Basal keratinocytes are the proliferative cells of the
epidermis. To stimulate basal keratinocyte proliferation, AR
and HB-EGF must act in a paracrine/autocrine and juxtacrine
manner. We were unable to determine whether AR and HB-
EGF made by basal and suprabasal layers are equally
functional. However, we demonstrate that AR and HB-EGF
both contribute to and are direct mediators of retinoid-
induced epidermal hyperplasia, using blocking antibodies in
skin organ cultures. Control IgGs, at higher concentrations,
caused nonspecific inhibition of keratinocytes growth. There-
fore, we were not able to reliably assess the combined effect
of AR and HB-EGF antibodies.
We demonstrated that a 32-hour tRA treatment induces
activation of the EGFR pathway in human epidermis in vivo
as measured by phosphorylated Erk1/2. To further demon-
strate the central role of EGFR activation in tRA-mediated
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epidermal hyperplasia, we used genistein. Genistein is a
potent inhibitor of EGFR tyrosine kinase activity (Akiyama
et al., 1987) that has previously been shown to block UV-
induced EGFR activation in human skin in vivo (Kang et al.,
2003), and to reduce retinoid-mediated epidermal hyper-
plasia in skin organ culture (Varani et al., 2004). Here,
we demonstrate that topical genistein significantly reduces
retinoid-mediated basal keratinocyte proliferation and epi-
dermal hyperplasia. Interestingly, we observe that genistein
does not prevent retinoid-mediated upregulation of AR or
HB-EGF, demonstrating that EGFR activation is downstream
of AR and HB-EGF induction. In contrast, it has been shown
that the EGFR/Erk pathway regulates the transcription of
several EGFR ligands in cultured keratinocytes. For instance,
activation of EGFR by EGF increases the transcription of AR,
HB-EGF, and TGF-a (Stoll and Elder, 1999), and the selective
MAPK/Erk kinase inhibitor PD98059 downregulates HB-EGF
mRNA (Pascall et al., 2000).
The most prominent side effect of topical retinoid
treatment is excessive scaling (Weiss et al., 1988). Scaling
is a direct consequence of retinoid-induced hyperplasia, as
keratinocytes that are induced to proliferate in the lower
epidermis must mature into corneocytes, and desquamate at
the skin surface. Our study demonstrates that tRA-induced
epidermal hyperplasia is mediated by EGFR ligands AR and
HB-EGF, in both basal and suprabasal epidermal layers.
Inhibition of EGFR activity by compounds such as genistein
may mitigate unwanted scaling caused by topical retinoid
treatment, and thereby improve compliance.
MATERIALS AND METHODS
Retinoid treatment and tissue procurement
All procedures involving human subjects were approved by the
University of Michigan Institutional Review Board, and all subjects
provided written informed consent before being enrolled in the
study. Experiments were carried out in adherence to the Declaration
of Helsinki Principles.
Adult volunteers were treated topically with tRA, tROL, or
vehicle (seven parts 95% ethanol and three parts propylene glycol
(vol/vol)), under occlusion, on sun-protected buttock skin. Duration
of treatments varied from 8 to 96 hours as indicated in figure legends.
For each subject, treated sites were separated by at least 2.5 cm.
Vehicle treatment was for 24 hours or 4 days, and did not alter
EGFR ligand transcript levels, compared to untreated skin (data
not shown). In some experiments, 1% genistein was applied to skin
simultaneously with tRA, tROL, or vehicle. After treatment, full-
thickness punch biopsies were obtained from each site. For RNA and
protein isolation, tissue samples (6-mm punches) were snap-frozen
in liquid nitrogen and stored at 801C until processing. For
immunohistochemistry and laser capture microdissection studies,
tissue samples (4-mm punches) were embedded in Tissue-Tek OCT
compound (Miles, Naperville, IL) before freezing.
RNA isolation and quantitative real-time reverse transcription-
PCR
Total RNA from vehicle- or retinoid-treated human skin was
extracted using a commercial kit (RNeasy, Qiagen, Chatsworth,
CA). The levels of mRNA expression were quantified by real-time
PCR as described previously (Quan et al., 2001). PCR primers and
probes, produced by the custom oligonucleotide synthesis service
(Applied Biosystems, Foster City, CA), are described in Table 1.
Target gene mRNA levels were normalized to 36B4 (housekeeping
gene) mRNA levels. Efficiency of real-time RT-PCR reactions was
determined using cDNA standards for TGF-a, HB-EGF, and AR.
Laser capture microdissection
Frozen sections (7–10 mm thick) were collected onto polyethylene
naphthalate foil-coated slides (Leica Microsystems, Bannockburn, IL)
and allowed to air-dry for 5 minutes. Sections were fixed in 75%
ethanol for 30 seconds and stained by immersion with hematoxylin
and eosin, using the following protocol: 30 seconds DEPC-treated
water, 15 seconds hematoxylin, 30 seconds DEPC-treated water,
10 seconds eosin, 30 seconds 75% ethanol, 30 seconds 95% ethanol,
and twice 30 seconds 100% ethanol. Slides were allowed to air-dry
for 5 minutes, and laser capture microdissection was performed
using a Leica AS LMD to obtain basal (first cell layer in contact
with the basement membrane) and suprabasal (remaining epidermis)
keratinocytes. Captured cells were collected directly into RNA
Table 1. Sequences of human primers and probes used for real-time PCR
Gene (labeling) Sense primer (50-30) Antisense primer (50-30) Probe (50-30)
AR (FAM) GGCCATTATGCTGCTGGAT TGTGGTCCCCAGAAAATGGT TGTGGTCCCCAGAAAATGGT
BTC (FAM) GGGAGATGCCGCTTCGT TGCTCCAATGTAGCCTTCATCA CCGAGCAGACGCCCTCCTGTG
EGF (FAM) AATACCGTTAAGATACAGTGTAGGCACTTTA ATCACAACTCATTTTGGCAAAATC CTCCTCATTGGCGTGGTCCATGCTGAT
Epiregulin (FAM) GGCTCCTTCATCGAATGCTAA CAGGATAAACGTAGAGGAAGAACAGA CCTTTGAGTAGAGTCTCCCTGGATCACATACCA
HB-EGF (FAM) TGGCCCTCCACTCCTCATC GGGTCACAGAACCATCCTAGCT CACCCACCTTTGCCACA
TGF-a (FAM) AGGACAGCACTGCCAGAGATG CGACGGAGTTCTTGACAGAGTTT CTGTGCAGCCTTTTGTGGGCCTTC
Keratin 5 (FAM) CCAGGAGAGCCCCATTCC GAAACCTGAAGGCTGATTTGAAG TGGTCTCCCGTGCCGCAGTTC
Keratin 10 (FAM) TCTGGCCGCGGATGACT CCATTGATGTCGGCTTCCA CTCATGCGCAGGTTCAACTCTGTCTCAT
36B4 (VIC) ATGCAGCAGATCCGCATGT TTGCGCATCATGGTGTTCTT CGCGGGAAGGCTGTGGTGCT
AR=amphiregulin; BTC=betacellulin; HB-EGF=heparin-binding EGF-like growth factor; PCR=polymerase chain reaction; TGF-a=transforming growth
factor-a.
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isolation lysis buffer (RNeasy kit; Qiagen), supplemented with RNase
inhibitor (Applied Biosystems) before RNA extraction.
Human skin organ cultures
Two-mm full-thickness punch biopsies of sun-protected buttock skin
were used for skin organ cultures, conducted as described previously
(Varani et al., 2001). For some experiments, culture medium was
supplemented with 3mRA, 10 mg/ml neutralizing antibodies to
HB-EGF (R&D Systems, Minneapolis, MN), 25 mg/ml neutralizing
antibodies to AR (R&D Systems), or the corresponding concentration
of control IgG (R&D Systems). At the end of the incubation period,
supernatants were harvested and assayed for HB-EGF and AR protein
(see below) and tissue was fixed in 10% formalin for histological
examination after hematoxylin and eosin staining. Epidermal
thickness was measured as described previously (Varani et al.,
2001).
Epidermal extract preparation and Western blotting
Epidermal extracts were prepared from frozen punch biopsies,
after removing the dermis using a sterile scalpel. Epidermis was
homogenized in ice-cold radioimmunoprecipitation assay buffer
(50 mM Tris-HCl, pH 7.6, 1% Ipegal, 0.25% Na deoxycholate,
150 mM NaCl, 1 mM EDTA, Protease inhibitors (complete mini;
Roche, Indianapolis, IN), 1 mM NO3VO4, 1 mM NaF), and vortexed
in the presence of glass beads (Biospec, Bartlesville, OK). After
10 minutes centrifugation at 10,000 g and 41C, supernatant was
assayed for total protein using BioRad Protein Assay reagent (BioRad,
Hercules, CA), and bovine serum albumin as a standard. Western
blotting were performed on 60 mg of epidermal extract, under
denaturing conditions, according to the method described pre-
viously (Quan et al., 2001). Antiphospho-Erk1/2 (Cell Signalling,
Danvers, MA) and anti-total Erk (Transduction Laboratories, BD
Biosciences, Franklin Lakes, NJ) were used at 1:1,000 dilutions.
AR and HB-EGF ELISA
AR ELISA was performed using a DuoSet human amphiregulin ELISA
kit (R&D Systems), according to the manufacturer’s instructions. HB-
EGF ELISA was performed according to the method described by
Yamada et al. (1998) and modified by Vinante et al. (1999). Amounts
of AR and HB-EGF protein were normalized with the total amount of
protein.
Immunohistochemisty for Ki-67
Seven-micrometer frozen sections were fixed in paraformaldehyde
and methanol, and stained with an antibody to the proliferation
marker Ki-67 (MAB4190; Chemicon, Temecula, CA) used at 1:500
dilution. Presence of tissue-bond primary antibodies was visualized
using a secondary antibody –peroxidase and AEC staining kit (Sigma,
St Louis, MO). The number of positive cells per unit length of
epidermis was evaluated using ImagePro Plus software.
Statistical analysis
Data are expressed as mean7standard error of the mean (SEM).
Comparisons among groups were made with the paired Student’s
t-test. When necessary, logarithmic transformations of the data were
made to achieve normalcy before analysis; however, the figures
depict the data on the untransformed scale. All P-values are two-
tailed, and considered significant when less than 0.05.
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